This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

Unmet Need in Multiple MyelomaMode of ActionAboutReimbursement InformationStudy OverviewStudy Design and Baseline DemographicsEfficacy OutcomesFollow-up Analyses OutcomesSafety ProfileMagnetisMM-3 StudySafetyDosingMaterialsVideosEventsSupport & Resources

The content of this website has been produced in line with the ELREXFIO®▼ (elranatamab) Summary of Product Characteristics. For Elrexfio® (elranatamab) Prescribing Information for United Kingdom click here.​

MagnetisMM-3 Study: Efficacy Outcomes
ELREXFIO® delivered deep responses in some patients with no prior BCMA-directed therapy*†1 

With a median follow-up of 15.2 months (range: 2.4-24.2):1

  • 61.0% (95% CI: 51.8-69.6; n=75) of BCMA-directed therapy-naïve patients (n=123) achieved an ORR (primary endpoint)†‡2 
    • 35.7% (n=44) of BCMA-directed therapy-naïve patients (n=123) achieved a complete response (secondary endpoint)*§2
  • 89.7% (95% CI: 72.7-97.8; n=26) of evaluable patients with a CR/sCR (n=29) achieved MRD negativity (secondary endpoint)¶2
    • ​​​​​​​Note, the analyses for minimal residual disease rate were not powered to detect statistical significance and should be interpreted with caution.
Primary endpoint: Objective response rate as assessed by BICR

Median duration of response (secondary endpoint)1,5

Adapted from ELREXFIO® Summary of Product Characteristics and Pfizer Data on File. REF-E1A2156.1,3

Median duration of follow-up for the primary endpoint was 15.2 months (range: 2.4-24.2)

The analyses for time to CR or better were not powered to detect statistical significance and should be interpreted with caution.

Responses were observed across a range of patient subgroups4

ORR by treatment- and disease-related factors4

Example

ORR by patient-related factors4

Example

Adapted from Pfizer Ltd. Data on File. REF-E1A2157.4

These data represent prespecified subgroup analyses and are presented for descriptive purposes only. Small patient numbers and lack of multiplicity adjustment can be limitations of these analyses. No conclusion about efficacy in subgroups can be drawn from these data.

Secondary endpoint: Median time to first response1,3

Adapted from ELREXFIO® Summary of Product Characteristics and Pfizer Data on File. REF-E1A2156.1,3

Median duration of follow-up for the primary endpoint was 15.2 months (range: 2.4-24.2)

The analyses for time to CR or better were not powered to detect statistical significance and should be interpreted with caution.

Secondary endpoint: Median time to complete response or better1,3

Adapted from ELREXFIO® Summary of Product Characteristics and Pfizer Data on File. REF-E1A2156.1,3

Median duration of follow-up for the primary endpoint was 15.2 months (range: 2.4-24.2)

The analyses for time to CR or better were not powered to detect statistical significance and should be interpreted with caution.

Duration of response and progression-free survival were key secondary endpoints in the MagnetisMM-3 study. At the time of primary analysis, median DoR and PFS were not met.1,6

ReferencesMagnetisMM-3 Follow-up Analyses Outcomes 

Read the MagnetisMM-3 Follow-up Analyses Outcomes for ELREXFIO®

Read moreLoading
*Deep response defined as ≥CR.
†As assessed by BICR.1
‡ORR defined as sCR+CR+VGPR+PR.1
§Complete response rate defined as sCR + CR.1
¶By threshold 10-5 next generation sequencing clonoSEQ assay.1
|| Median time to complete response or better is a measure of the median time for patients to reach a response defined as ≥CR. This analysis was completed as part of the time to response secondary endpoint.3
BCMA: B-cell maturation antigen; BICR: blinded independent central review; CI: confidence interval; CR: complete response; DoR: duration of response; ECOG PS: Eastern Cooperative Oncology Group performance status; MM: multiple myeloma; MRD: minimal residual disease; NE: not evaluable; OR: objective response; ORR: objective response rate; PR: partial response; R-ISS: revised international staging system; RRMM: relapsed or refractory multiple myeloma; sCR: stringent complete response; SmPC: Summary of Product Characteristics; VGPR: very good partial response; 
References:ELREXFIO® Summary of Product Characteristics.Pfizer Ltd. Data on File. REF-E1A2136.Pfizer Ltd. Data on File. REF-E1A2156.Pfizer Ltd. Data on File. REF-E1A2157.Kumar S, et al. Lancet Oncol. 2016;17:e328-3346.Lesohkin AM, et al. Nature Medicine 2023;29:2259-2267.
Eficacy Outcomes MagnetisMM-3 Study Follow-up Analyses Outcomes Read moreLoadingDosing Details of the recommended ELREXFIO® step-up dosing and administration instructions  Read moreLoadingSafety profileSafety profile of ELREXFIO® in all patients treated at the recommended dose in the Phase 2 MagnetisMM-3 study (n=183) Read moreLoading
PP-L1A-GBR-0552. January 2025

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2025 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-11245. January 2025
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​

You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​